keyword
https://read.qxmd.com/read/36689697/clinicopathologic-and-molecular-analysis-of-normal-karyotype-therapy-related-and-de-novo-acute-myeloid-leukemia-a-multi-institutional-study-by-the-bone-marrow-pathology-group
#21
MULTICENTER STUDY
Miguel D Cantu, Rashmi Kanagal-Shamanna, Sa A Wang, Tapan Kadia, Carlos E Bueso-Ramos, Sanjay S Patel, Julia T Geyer, Wayne Tam, Yazan Madanat, Peng Li, Tracy I George, Meredith M Nichols, Heesun J Rogers, Yen-Chun Liu, Nidhi Aggarwal, Jason H Kurzer, Danielle L V Maracaja, Eric D Hsi, Feras Zaiem, Daniel Babu, Kathryn Foucar, Dorottya Laczko, Adam Bagg, Attilio Orazi, Daniel A Arber, Robert P Hasserjian, Olga K Weinberg
PURPOSE: Therapy-related acute myeloid leukemias (t-AML) are a heterogenous group of aggressive neoplasms that arise following exposure to cytotoxic chemotherapy and/or ionizing radiation. Many therapy-related myeloid neoplasms (t-MN) are associated with distinct chromosomal aberrations and/or TP53 alterations, but little is known about the clinicopathologic and molecular features of normal karyotype t-AML (NK-t-AML) and whether this t-MN subtype is distinctly different from NK de novo AML (NK-dn-AML)...
January 2023: JCO Precision Oncology
https://read.qxmd.com/read/36538625/multifunctional-cu-2-tsis-4-t-mn-and-fe-polar-semiconducting-antiferromagnets-with-nonlinear-optical-properties
#22
JOURNAL ARTICLE
Zachary T Messegee, Jun Sang Cho, Andrew J Craig, V Ovidiu Garlea, Yan Xin, Chang-Jong Kang, Thomas E Proffen, Hari Bhandari, Jordan C Kelly, Nirmal J Ghimire, Jennifer A Aitken, Joon I Jang, Xiaoyan Tan
Cu2 TSiS4 (T = Mn and Fe) polycrystalline and single-crystal materials were prepared with high-temperature solid-state and chemical vapor transport methods, respectively. The polar crystal structure (space group Pmn 21 ) consists of chains of corner-sharing and distorted CuS4 , Mn/FeS4 , and SiS4 tetrahedra, which is confirmed by Rietveld refinement using neutron powder diffraction data, X-ray single-crystal refinement, electron diffraction, energy-dispersive X-ray spectroscopy, and second harmonic generation (SHG) techniques...
December 20, 2022: Inorganic Chemistry
https://read.qxmd.com/read/36412033/-two-cases-of-therapy-related-myeloid-neoplasms-after-docetaxel-with-cyclophosphamide-therapy-for-breast-cancer
#23
JOURNAL ARTICLE
Tomoko Itagaki, Yuri Kimura, Hideaki Shigematsu
Docetaxel with cyclophosphamide(TC)is used as a perioperative chemotherapy. Therapy-related myeloid neoplasms(t- MN)are a rare adverse event of TC therapy. We report 2 cases of t-MN after TC therapy for breast cancer. Case 1 involved a 72-year-old woman who received 4 courses of TC therapy and radiation therapy after surgery. Two years and eight months after surgery, she presented with night sweats, coughing, headaches, and a low-grade fever. Laboratory examination revealed leukocytosis, and a bone marrow aspiration biopsy confirmed acute myelogenous leukemia with myeloid morphology- related changes and secondary acute myelogenous leukemia...
November 2022: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://read.qxmd.com/read/36349721/inherited-cancer-predisposing-mutations-in-patients-with-therapy-related-myeloid-neoplasms
#24
JOURNAL ARTICLE
Andrew J Shih, Tomi Jun, Andrew D Skol, Riyue Bao, Lei Huang, Sapana Vora, Megan E McNerney, Eric A Hungate, Michelle M Le Beau, Richard A Larson, Aaron Elliott, Hsiao-Mei Lu, Robert Huether, Felicia Hernandez, Friedrich Stölzel, James M Allan, Kenan Onel
Some patients with therapy-related myeloid neoplasms (t-MN) may have unsuspected inherited cancer predisposition syndrome (CPS). We propose a set of clinical criteria to identify t-MN patients with high risk of CPS (HR-CPS). Among 225 t-MN patients with an antecedent non-myeloid malignancy, our clinical criteria identified 52 (23%) HR-CPS patients. Germline whole-exome sequencing identified pathogenic or likely pathogenic variants in 10 of 27 HR-CPS patients compared to 0 of 9 low-risk CPS patients (37% vs...
February 2023: British Journal of Haematology
https://read.qxmd.com/read/36332258/thermodynamic-interpretation-of-the-meyer-neldel-rule-explains-temperature-dependence-of-ion-diffusion-in-silicate-glass
#25
JOURNAL ARTICLE
N Takamure, X Sun, T Nagata, A Ho-Baillie, N Fukata, D R McKenzie
We study the temperature-dependent diffusion of many types of metal and semimetal ions in soda-lime glass using thermal relaxation ion spectroscopy, a technique that provides an electrical readout of thermally activated diffusion of charge carriers driven by built-in concentration gradients and electric fields. We measure the temperature of the onset of the motion, relevant to the long term storage of radioactive elements. We demonstrate the unique behavior of silver in soda-lime glass, enabling a thermal battery with rapid discharge of stored energy above a threshold temperature...
October 21, 2022: Physical Review Letters
https://read.qxmd.com/read/36219593/clonal-hematopoiesis-in-patients-with-stem-cell-mobilization-failure-a-nested-case-control-study
#26
JOURNAL ARTICLE
Carin Hazenberg, Aniek O de Graaf, René Mulder, Laura Bungener, Maaike G J M van Bergen, André B Mulder, Goda Choi, Jan Jacob Schuringa, Marco de Groot, Edo Vellenga, Joop H Jansen, Gerwin Huls, Isabelle A van Zeventer
Inadequate mobilization of peripheral blood progenitor cells (PBPC) is a limiting factor to proceed with autologous hematopoietic cell transplantation (auto-HCT). To assess the impact of clonal hematopoiesis (CH) on mobilization failure of PBPC for auto-HCT, we investigated the characteristics of poor mobilizers (with total PBPC collection <2x106 CD34+ cells/kg) in a consecutive single center cohort of 776 patients. Targeted error corrected next-generation sequencing of 28 genes was performed in a nested case-control cohort of 90 poor mobilizers and 89 matched controls...
October 11, 2022: Blood Advances
https://read.qxmd.com/read/36201165/therapy-related-myeloid-neoplasms-following-parp-inhibitors-real-life-experience
#27
JOURNAL ARTICLE
Vincent Marmouset, Justine Decroocq, Sylvain Garciaz, Gabriel Etienne, Amine Belhabri, Sarah Bertoli, Lauris Gastaud, Célestine Simand, Sylvain Chantepie, Madalina Uzunov, Alexis Genthon, Céline Berthon, Edmond Chiche, Pierre-Yves Dumas, Jacques Vargaftig, Géraldine Salmeron, Emilie Lemasle, Emmanuelle Tavernier, Jérémy Delage, Marion Loirat, Nadine Morineau, Félix Blanc-Durand, Patricia Pautier, Véronique Vergé, Nathalie Auger, Myrtille Thomas, Laetitia Stefani, Marion Lepelley, Thomas Boyer, Sylvain Thepot, Marie-Pierre Gourin, Pascal Bourquard, Matthieu Duchmann, Pierre-Marie Morice, Mauricette Michallet, Lionel Adès, Pierre Fenaux, Christian Récher, Hervé Dombret, Arnaud Pagès, Christophe Marzac, Alexandra Leary, Jean-Baptiste Micol
PURPOSE: To provide insights into the diagnosis and management of therapy-related myeloid neoplasms (t-MN) following PARP inhibitors (PARPi). EXPERIMENTAL DESIGN: In a French cancer center, we identified and described the profiles of 13 t-MN diagnosed among 37 patients with ovarian cancer referred to hematology consultation for cytopenia under PARPi. Next, we described these 13 t-MN post-PARPi among 37 t-MN post ovarian cancer according to PARPi exposure. Finally, we described 69 t-MN post-PARPi in a national cohort...
December 1, 2022: Clinical Cancer Research
https://read.qxmd.com/read/36149440/-clonal-hematopoiesis-and-solid-neoplasms
#28
REVIEW
Christopher Maximilian Arends, Frederik Damm
BACKGROUND: Clonal hematopoiesis (CH) is a premalignant state of the hematopoietic system that frequently occurs in old age and is associated with an elevated cardiovascular risk and higher overall mortality. AIM: The prevalence and clinical implications of CH in patients with solid neoplasms were examined. MATERIAL AND METHODS: A review, summary and discussion of the recent literature was carried out. RESULTS: CH occurs in 20-30% of patients with solid neoplasms...
September 23, 2022: Inn Med (Heidelb)
https://read.qxmd.com/read/36069361/epidemiologic-outlook-of-therapy-related-myeloid-neoplasms-and-selection-of-high-risk-patients-a-korean-nationwide-study
#29
JOURNAL ARTICLE
Hyerim Ha, Hyo Jeong Kim, Ju Hyun Park, Aesun Shin, Kyu Na Lee, Kyungdo Han, Na Rae Lee, Junshik Hong
BACKGROUND: Although a considerable proportion of patients with cancer receive chemotherapy (CT) or radiotherapy (RT), only a very few patients eventually develop therapy-related myeloid neoplasms (t-MNs). METHODS: To identify subsets of cancer patients who have substantially elevated risk of developing t-MNs. Incidences and risks of t-MNs after contemporary CT or RT in patients newly diagnosed major cancers during 2009-2013 were analyzed. By merging two Korean nationwide health care big data sets, patients were selected and observed on follow-up to until t-MN development or December 2019...
September 7, 2022: Cancer
https://read.qxmd.com/read/36030518/therapy-related-myeloid-neoplasms-of-recipient-origin-after-allogeneic-hematopoietic-stem-cell-transplantation-for-acute-leukemia
#30
JOURNAL ARTICLE
Takumi Hoshino, Nahoko Hatsumi, Hiromasa Iino, Satoru Takada
Some allogeneic stem cell transplantation (allo-SCT) recipients develop therapy-related myeloid neoplasms (t-MNs) of recipient origin with features including karyotypically abnormal hematopoiesis without cell dysplasia and myeloblast increase. However, due to their rarity their clinical course remains unclear. We report six cases of t-MN in patients with chromosomal abnormalities (CAs) after autologous recovery following allo-SCT for acute leukemia. CAs were first detected at a median interval of 422 (range 30-1941) days from allo-SCT...
August 28, 2022: International Journal of Hematology
https://read.qxmd.com/read/35986863/role-of-germline-predisposition-to-therapy-related-myeloid-neoplasms
#31
REVIEW
Anmol Baranwal, Christopher N Hahn, Mithun Vinod Shah, Devendra K Hiwase
PURPOSE OF REVIEW: Therapy-related myeloid neoplasms (t-MNs) are aggressive leukemias that develop following exposure to DNA-damaging agents. A subset of patients developing t-MN may have an inherited susceptibility to develop myeloid neoplasia. Herein, we review studies reporting t-MN and their association with a germline or inherited predisposition. RECENT FINDINGS: Emerging evidence suggests that development of t-MN is the result of complex interactions including generation of somatic variants in hematopoietic stem cells and/or clonal selection pressure exerted by the DNA-damaging agents, and immune evasion on top of any inherited genetic susceptibility...
August 20, 2022: Current Hematologic Malignancy Reports
https://read.qxmd.com/read/35803921/therapy-related-clonal-cytopenia-as-a-precursor-to-therapy-related-myeloid-neoplasms
#32
JOURNAL ARTICLE
Mithun Vinod Shah, Abhishek A Mangaonkar, Kebede H Begna, Hassan B Alkhateeb, Patricia Greipp, Ahmad Nanaa, Michelle A Elliott, William J Hogan, Mark R Litzow, Kristen McCullough, Ayalew Tefferi, Naseema Gangat, Mrinal M Patnaik, Aref Al-Kali, Rong He, Dong Chen
Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC had a distinct genetic and cytogenetic profile: pathogenic variants (PV) in TET2 and SRSF2 were enriched in t-CC, whereas TP53 PV was more common in t-MN...
July 8, 2022: Blood Cancer Journal
https://read.qxmd.com/read/35770528/routine-clinical-parameters-and-laboratory-testing-predict-therapy-related-myeloid-neoplasms-after-treatment-for-breast-cancer
#33
JOURNAL ARTICLE
Giulia Petrone, Charles Gaulin, Andriy Derkach, Ashwin Kishtagari, Mark E Robson, Rekha Parameswaran, Eytan M Stein
We aim to identify predictors of therapy-related myeloid neoplasms (t-MN) in patients with breast cancer (BC) and cytopenias to determine the timing of bone marrow biopsy (BMBx). Patients with BC and cytopenias who were referred for BMBx between 2002-2018 were identified using the Memorial Sloan Kettering Cancer Center institutional database. Characteristics associated with the risk of t-MN were evaluated by multivariable logistic regression and included in a predictive model. The average area under the receiver operating characteristic curve (AUC) was estimated by 5-fold cross-validation...
June 30, 2022: Haematologica
https://read.qxmd.com/read/35733964/soil-microbial-communities-affect-the-growth-and-secondary-metabolite-accumulation-in-bletilla-striata-thunb-rchb-f
#34
JOURNAL ARTICLE
Chenghong Xiao, Chunyun Xu, Jinqiang Zhang, Weike Jiang, Xinqing Zhang, Changgui Yang, Jiao Xu, Yongping Zhang, Tao Zhou
Bletilla striata (Thunb.) Rchb.f. is a perennial herb belonging to the Orchidaceae family. Its tubers are used in traditional Chinese medicine to treat gastric ulcers, inflammation, silicosis tuberculosis, and pneumogastric hemorrhage. It has been reported that different soil types can affect the growth of B. striata and the accumulation of secondary metabolites in its tubers, but the biological mechanisms underlying these effects remain unclear. In this study, we compared agronomic traits and the accumulation of secondary metabolites (extractum, polysaccharide, total phenol, militarine) in B...
2022: Frontiers in Microbiology
https://read.qxmd.com/read/35678530/elevated-mutational-age-in-blood-of-children-treated-for-cancer-contributes-to-therapy-related-myeloid-neoplasms
#35
JOURNAL ARTICLE
Eline J M Bertrums, Axel K M Rosendahl Huber, Jurrian K de Kanter, Arianne M Brandsma, Anaïs J C N van Leeuwen, Mark Verheul, Marry M van den Heuvel-Eibrink, Rurika Oka, Markus J van Roosmalen, Hester A de Groot-Kruseman, C Michel Zwaan, Bianca F Goemans, Ruben van Boxtel
Childhood cancer survivors are confronted with various chronic health conditions like therapy-related malignancies. However, it is unclear how exposure to chemotherapy contributes to the mutation burden and clonal composition of healthy tissues early in life. Here, we studied mutation accumulation in hematopoietic stem and progenitor cells (HSPC) before and after cancer treatment of 24 children. Of these children, 19 developed therapy-related myeloid neoplasms (t-MN). Posttreatment HSPCs had an average mutation burden increase comparable to what treatment-naïve cells accumulate during 16 years of life, with excesses up to 80 years...
August 5, 2022: Cancer Discovery
https://read.qxmd.com/read/35560061/outcomes-following-venetoclax-based-treatment-in-therapy-related-myeloid-neoplasms
#36
JOURNAL ARTICLE
Mithun Vinod Shah, Rakchha Chhetri, Ruchita Dholakia, Chung H Kok, Naseema Gangat, Hassan B Alkhateeb, Aref Al-Kali, Mrinal M Patnaik, Anmol Baranwal, Patricia T Greipp, Rong He, Kebede H Begna, Ing Soo Tiong, Andrew H Wei, Devendra Hiwase
Therapy-related myeloid neoplasms (t-MN) are aggressive malignancies in need of effective therapies. The BCL-2 inhibitor venetoclax represents a paradigm shift in the treatment of acute myeloid leukemia. However, the effectiveness of venetoclax has not been studied in a large cohort of t-MN. We retrospectively analyzed 378 t-MN patients, of which 96 (25.4%, 47 therapy-related acute myeloid leukemia, 1 therapy-related chronic myelomonocytic leukemia, 48 therapy-related myelodysplastic syndrome) received venetoclax...
August 2022: American Journal of Hematology
https://read.qxmd.com/read/35512188/lenalidomide-promotes-the-development-of-tp53-mutated-therapy-related-myeloid-neoplasms
#37
JOURNAL ARTICLE
Adam S Sperling, Veronica A Guerra, James A Kennedy, Yuanqing Yan, Joanne I Hsu, Feng Wang, Andrew T Nguyen, Peter G Miller, Marie E McConkey, Vanessa A Quevedo Barrios, Ken Furudate, Linda Zhang, Rashmi Kanagal-Shamanna, Jianhua Zhang, Latasha Little, Curtis Gumbs, Naval Daver, Courtney D DiNardo, Tapan Kadia, Farhad Ravandi, Hagop Kantarjian, Guillermo Garcia-Manero, P Andrew Futreal, Benjamin L Ebert, Koichi Takahashi
There is a growing body of evidence that therapy-related myeloid neoplasms (t-MNs) with driver gene mutations arise in the background of clonal hematopoiesis (CH) under the positive selective pressure of chemo- and radiation therapies. Uncovering the exposure relationships that provide selective advantage to specific CH mutations is critical to understanding the pathogenesis and etiology of t-MNs. In a systematic analysis of 416 patients with t-MN and detailed prior exposure history, we found that TP53 mutations were significantly associated with prior treatment with thalidomide analogs, specifically lenalidomide...
October 20, 2022: Blood
https://read.qxmd.com/read/35459878/allogeneic-hematopoietic-cell-transplantation-in-patients-with-therapy-related-myeloid-neoplasm-after-breast-cancer-a-study-of-the-chronic-malignancies-working-party-of-the-ebmt
#38
JOURNAL ARTICLE
Mitja Nabergoj, Katya Mauff, Dietrich Beelen, Arnold Ganser, Nicolaus Kröger, Friedrich Stölzel, Jürgen Finke, Jakob Passweg, Jan Cornelissen, Natalie Schub, Joan Hendrik Veelken, Yves Beguin, Keith Wilson, Tsila Zuckerman, Mathilde Hunault-Berger, Bruno Lioure, Rocio Parody Porras, Pascal Turlure, Tessa Kerre, Linda Koster, Patrick J Hayden, Francesco Onida, Christof Scheid, Yves Chalandon, Marie Robin, Ibrahim Yakoub-Agha
We performed a registry study on therapy-related myeloid neoplasm (t-MN), both therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) following treatment for breast cancer who underwent a first allogeneic hematopoietic cell transplant (allo-HCT). Of 252 identified female patients (median age 57 years), 77% were transplanted for t-AML and 23% for t-MDS, with a median time from breast cancer diagnosis to the diagnosis of tMN and subsequent allo-HCT of 3.7 and 4.6 years, respectively...
July 2022: Bone Marrow Transplantation
https://read.qxmd.com/read/35380821/dimerization-of-paramagnetic-trinuclear-complexes-by-coordination-geometry-changes-showing-mixed-valency-and-significant-antiferromagnetic-coupling-through-pt%C3%A2-%C3%A2-%C3%A2-pt-bonds
#39
JOURNAL ARTICLE
Atsushi Takamori, Kazuhiro Uemura
Paramagnetic trinuclear complexes, trans -[Pt2 M(piam)4 (NH3 )4 ](ClO4 ) x ( t -M ; piam = pivalamidate, M = Mn, Fe, Co, Ni, and Cu, x = 2 or 3), aligned as Pt-M-Pt were successfully synthesized and characterized. The dihedral angles between the Pt and M coordination planes in t -M are approximately parallel, showing straight metal-metal bonds with distances of approximately 2.6 Å. Except for t -Fe , the trinuclear complexes are dimerized with close contact (approximately 3.9 Å) between the end Pt atoms to form Pt-M-Pt···Pt-M-Pt alignments with high-spin M(+2) containing five ( t -Mn ), three ( t -Co ), two ( t -Ni ), and one ( t -Cu ) unpaired electrons localized on M atoms...
April 5, 2022: Inorganic Chemistry
https://read.qxmd.com/read/35380239/the-role-of-clonal-hematopoiesis-as-driver-of-therapy-related-myeloid-neoplasms-after-autologous-stem-cell-transplantation
#40
JOURNAL ARTICLE
Doriana Gramegna, Diego Bertoli, Chiara Cattaneo, Camillo Almici, Alessandro Re, Angelo Belotti, Erika Borlenghi, Gaetana Lanzi, Silvana Archetti, Rosanna Verardi, Duilio Brugnoni, Margherita Sciumè, Rosa Daffini, Aldo M Roccaro, Alessandra Tucci, Giuseppe Rossi
Therapy-related myeloid neoplasm (t-MN) is a threatening complication of autologous stem cell transplantation (ASCT). Detecting clonal hematopoiesis (CH) mutations in cryopreserved cells before ASCT has been associated with a higher risk of t-MN, but the evolution of molecular abnormalities from pre-ASCT to t-MN, within the same patient, remains to be elucidated. We evaluated the mutational profile of 19 lymphoma/myeloma patients, at both pre-ASCT and t-MN diagnosis, using a targeted NGS approach; 26 non-developing t-MN control patients were also studied pre-ASCT...
April 5, 2022: Annals of Hematology
keyword
keyword
163655
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.